Jairam Krishnamurthy
Rating: 4.9 of 5
( out of 17 reviews )

Jairam Krishnamurthy, MD, FACP

Languages spoken: English, Hindi, Tamil

  • Dr. Jairam Krishnamurthy is a board-certified academic medical oncologist with specialized expertise in the management of breast cancer across its diverse subtypes. He joined Huntsman Cancer Institute at the University of Utah on July 7, 2025, as Associate Professor of Medicine in the Division of Oncology and holds the HCI Endowed Chair in Women’s Cancer Research.

    At Huntsman, Dr. Krishnamurthy leads the Breast Cancer Clinical Trials Research Group, where he is committed to developing a robust and inclusive clinical trial portfolio. His work spans industry-sponsored, cooperative group, and investigator-initiated studies, all aimed at expanding access to innovative therapies and promoting equitable participation in breast cancer research.

    As Co-Leader of the Breast and Gynecologic Cancer Center, he fosters interdisciplinary collaboration between basic scientists and clinical teams, enhances operational efficiency in breast cancer services, and advances community outreach and engagement.

    Prior to joining Huntsman, Dr. Krishnamurthy spent a decade at the University of Nebraska Medical Center, where he served as Medical Director of the Breast Cancer Program and led the Breast Cancer Clinical Trials Research Group. He was Principal Investigator on numerous clinical trials, including several investigator-initiated studies he personally developed, and served as Associate Director of the Hematology and Medical Oncology Fellowship Program for five years.

    From 2018 to 2025, he was a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, contributing to the development of national standards in breast cancer care.

    Dr. Krishnamurthy’s professional mission is to deliver exceptional patient care, expand access to cutting-edge research, support the career development of junior faculty, and mentor the next generation of oncology professionals. He is enthusiastic about the opportunities at Huntsman Cancer Institute and looks forward to advancing the breast cancer program through innovation and collaboration.

    Specialties

    Board Certification

    Educational Commission for Foreign Medical Graduates
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 17 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    The doctor was very thorough, explained things in great detail, but to understand. He is one of the best.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    She is very professional; I liked her manner and her attention. Thank you very much for your professionalism. [TRANSLATED]

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Krishnamurthy is wonderful, and I can't say enough good things about him. He explained everything to me in a way that allowed me to understand exactly what is going on and what I can expect in the future, when it come to treatments and my cancer journey. He went above and beyond to make me feel comfortable and help me. I am very grateful that he is my doctor.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Jairam Krishnamurthy, MD is a blessing to our family. He is extremely intelligent, kind, and shows a great deal of care towards his patients.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He is amazing. He knew my chronological profile better than I did.

  • Dr. Jairam Krishnamurthy is a board-certified academic medical oncologist with specialized expertise in the management of breast cancer across its diverse subtypes. He joined Huntsman Cancer Institute at the University of Utah on July 7, 2025, as Associate Professor of Medicine in the Division of Oncology and holds the HCI Endowed Chair in Women’s Cancer Research.

    At Huntsman, Dr. Krishnamurthy leads the Breast Cancer Clinical Trials Research Group, where he is committed to developing a robust and inclusive clinical trial portfolio. His work spans industry-sponsored, cooperative group, and investigator-initiated studies, all aimed at expanding access to innovative therapies and promoting equitable participation in breast cancer research.

    As Co-Leader of the Breast and Gynecologic Cancer Center, he fosters interdisciplinary collaboration between basic scientists and clinical teams, enhances operational efficiency in breast cancer services, and advances community outreach and engagement.

    Prior to joining Huntsman, Dr. Krishnamurthy spent a decade at the University of Nebraska Medical Center, where he served as Medical Director of the Breast Cancer Program and led the Breast Cancer Clinical Trials Research Group. He was Principal Investigator on numerous clinical trials, including several investigator-initiated studies he personally developed, and served as Associate Director of the Hematology and Medical Oncology Fellowship Program for five years.

    From 2018 to 2025, he was a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, contributing to the development of national standards in breast cancer care.

    Dr. Krishnamurthy’s professional mission is to deliver exceptional patient care, expand access to cutting-edge research, support the career development of junior faculty, and mentor the next generation of oncology professionals. He is enthusiastic about the opportunities at Huntsman Cancer Institute and looks forward to advancing the breast cancer program through innovation and collaboration.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    Educational Commission for Foreign Medical Graduates
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine

    Education history

    Professional Medical Medicine - All India Institute of Medical Sciences M.D.
    Internship All India Institute of Medical Sciences Intern
    Residency Radiation Oncology - All India Institute of Medical Sciences Junior Resident
    Residency Ophthalmology - All India Institute of Medical Sciences Junior Resident
    Postdoctoral Fellowship Hematopoietic Stem Cell Transplantation Program - Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology Postdoctoral Research Fellow
    Internship Internal Medicine - The Carle Illinois College of Medicine Intern
    Residency Internal Medicine - Creighton University Medical Center Resident
    Fellowship Oncology/Hematology - University of Nebraska Medical Center Fellow

    Selected Publications

    Journal Article

    1. Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J, Evens A, Frankfurt O, Altman J, Gordon L, Tallman M, Williams S, Winter J, Singhal S, Mehta (2009). Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?. Bone marrow transplantation, 43(4), 301-5. (Read full publication)
    2. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta (2009). The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood, 114(1), 38-9. (Read full publication)
    3. Mehta J, Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal (2009). Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leukemia & lymphoma, 50(9), 1434-41. (Read full publication)
    4. Gonsalves WI, Tashi T, Krishnamurthy J, Davies T, Ortman S, Thota R, Aldoss I, Ganta A, Kalaiah M, Didwaniya N, Eberle C, Ganti AK, Silberstein PT, Subbiah (2011). Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population. Journal of palliative medicine, 14(11), 1231-5. (Read full publication)
    5. Gonsalves WI, Kanuri S, Tashi T, Aldoss I, Sama A, Al-Howaidi I, Ganta A, Kalaiah M, Thota R, Krishnamurthy J, Fang X, Townley P, Ganti AK, Subbiah S, Silberstein P (2011). Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: a Veterans' Affairs Central Cancer Registry (VACCR) database analysis. Journal of surgical oncology, 104(6), 667-71. (Read full publication)
    6. Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang (2014). Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare tumors, 6(1), 5043. (Read full publication)
    7. Aryal MR, Bhatt VR, Tandra P, Krishnamurthy J, Yuan J, Greiner TC, Akhtari (2014). Autoimmune neutropenia in multiple myeloma and the role of clonal T-cell expansion: evidence of cross-talk between B-cell and T-cell lineages?. Clinical lymphoma, myeloma & leukemia, 14(1), e19-23. (Read full publication)
    8. Bhatt VR, Shrestha R, Krishnamurthy J, Mosalpuria K, Loberiza FR Jr, Ganti AK, Silberstein P (2015). Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base. Therapeutic advances in medical oncology, 7(1), 4-11. (Read full publication)
    9. Kommalapati A, Tella SH, Goyal G, Ganti AK, Krishnamurthy J, Tandra P (2018). A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer. Breast cancer research and treatment, 170(3), 677-685. (Read full publication)
    10. Krishnamurthy J, Luo J, Suresh R, Ademuyiwa F, Rigden C, Rearden T, Clifton K, Weilbaecher K, Frith A, Roshal A, Tandra PK, Cherian M, Summa T, Haas B, Thomas S, Hernandez-Aya L, Bergqvist M, Peterson L, Ma C (2022). A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. NPJ breast cancer, 8(1), 35. (Read full publication)
    11. Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL, Wang X, Luo SJ, Zhou K, Du P, Jia S, King BL, Krishnamurthy J, Ma C (2023). Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. Clinical cancer research, 29(9), 1719-1729. (Read full publication)
    12. Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky R (2024). Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO precision oncology, 8, e2300513. (Read full publication)
    13. Kesireddy M, Elsayed L, Shostrom VK, Agarwal P, Asif S, Yellala A, Krishnamurthy (2024). Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis. Cancers, 16(10), (Read full publication)
    14. Jiang H, Cartwright S, Wagner DG, Krishnamurthy J, Santamaria-Barria J (2024). Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Postpartum High-Risk Basal-Type Breast Cancer. Cureus, 16(6), e62338. (Read full publication)
    15. Elsayed L, Reed E, Modi S, Tandra PK, Copur MS, Samson K, Krishnamurthy (2024). Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide with Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. Clinical breast cancer, 24(8), 676-682.e1. (Read full publication)
    16. Khandalavala B, Carlson S, Elsayed L, Geske J, Krishnamurthy (2024). Diet Quality in Patients with Breast Cancer: Results of a Single Cohort Study in a Midwestern US Population. . Nutrition and cancer, 1-9. (Read full publication)
    17. Kuhlers SL, Kathol E, Hartnett-Quach D, Krishnamurthy J, Marth (2024). Assessing Outcomes of Tapering 12-Hour and 6-Hour Dexamethasone Prior to Paclitaxel Infusions in Patients with Breast Cancer. Clinical breast cancer, (Read full publication)
    18. Pan T, Alimi OA, Liu B, Krishnan MA, Kuss M, Shi W, Krishnamurthy J, Dong JJ, Oberley-Deegan RE, Duan B (2025). Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Reports (MDPI),
    19. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar (2024). Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(5), 331-357. (Read full publication)
    20. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar (2023). NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. Journal of the National Comprehensive Cancer Network, 21(6), 594-608. (Read full publication)
    21. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar (2022). Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(6), 691-722. (Read full publication)
    22. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar (2021). NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network, 19(5), 484-493. (Read full publication)
    23. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(4), 452-478. (Read full publication)
    24. William J. Gradishar, MD1,*; Meena S. Moran, MD2,*; Jame Abraham, MD3; Vandana Abramson, MD4; Rebecca Aft, MD, PhD5; Doreen Agnese, MD6; Kimberly H. Allison, MD7; Bethany Anderson, MD8; Janet Bailey, MD9; Harold J. Burstein, MD, PhD10; Nan Chen, MD11; Helen Chew, MD12; Chau Dang, MD13; Anthony D. Elias, MD14; Sharon H. Giordano, MD, MPH15; Matthew P. Goetz, MD16; Rachel C. Jankowitz, MD17; Sara H. Javid, MD18; Jairam Krishnamurthy, MD19; A. Marilyn Leitch, MD20; Janice Lyons, MD3,*; Susie McCloskey, MD, MSHS21; Melissa McShane, MD22; Joanne Mortimer, MD23; Sameer A. Patel, MD22; Laura H. Rosenberger, MD, MS24; Hope S. Rugo, MD25; Cesar A. Santa-Maria, MD, MSCI26,*; Bryan P. Schneider, MD27; Mary Lou Smith, JD, MBA28; Hatem Soliman, MD29; Erica M. Stringer-Reasor, MD30; Melinda L. Telli, MD7; Mei Wei, MD31,*; Kari B. Wisinski, MD8,*; Amulya Yellala, MBBS19; Kay T. Yeung, MD, PhD32,*; Jessica S. Young, MD33; Ryan Schonfeld, BA34,*; and Rashmi Kumar, PhD34, (2025). Invasive, Nonmetastatic Breast Cancer. Journal of the National Comprehensive Cancer Network, 23(11), 426-436.
    25. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar (2025). NCCN Guidelines® Insights: Breast Cancer, Version 5.2025. Journal of the National Comprehensive Cancer Network, 23(11), 426-436. (Read full publication)
    26. Pan T, Alimi OA, Liu B, Krishnan MA, Kuss M, Shi W, Krishnamurthy J, Dong JJ, Oberley-Deegan RE, Duan (2025). Therapeutic Potential of BMX-001 for Preventing Chemotherapy-Induced Peripheral Neuropathic Pain. Pharmaceuticals (Basel, Switzerland), 18(8), (Read full publication)
    27. Kesireddy M, Masih D, Shostrom VK, Yellala A, Asif S, Krishnamurthy (2025). Overall Survival and Prognostic Factors in De Novo Metastatic Human Epidermal Growth Factor Receptor (HER)-2-Positive Breast Cancer: A National Cancer Database Analysis. Cancers, 17(11), (Read full publication)
    28. Alves TF, Crosby K, Horner RD, Dai HD, Krishnamurthy J, Cozad M (2025). Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study. JMIR research protocols, 14, e66050. (Read full publication)

    Review

    1. Tandra P, Krishnamurthy J, Bhatt VR, Newman K, Armitage JO, Akhtari (2013). Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths. Mediterranean journal of hematology and infectious diseases, 5(1), e2013068. (Read full publication)
    2. Akhtari M, Bhatt VR, Tandra PK, Krishnamurthy J, Horstman H, Dreessen A, Chen PX, Armitage J (2013). Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer biology & therapy, 14(12), 1077-88. (Read full publication)
    3. Mainali NR, Bhatt VR, Kedia S, Krishnamurthy J, Wake LM, Akhtari (2014). Reversible bone marrow aplasia induced by pegylated interferon-¿-2a therapy in a patient with primary myelofibrosis. Journal of oncology pharmacy practice, 20(5), 386-92. (Read full publication)

    Commentary

    1. Tandra P, Kallam A, Krishnamurthy (2019). Identification and Management of Lymphedema in Patients With Breast Cancer. Journal of oncology practice, 15(5), 255-262. (Read full publication)
    2. Krishnamurthy J, Tandra P (2019). Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Common Complication With Effective Treatment Strategies. Journal of oncology practice, 15(7), 373-374. (Read full publication)
    3. Krishnan M, Krishnamurthy J, Shonka (2019). Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain. Oncology (Williston Park, N.Y.), 33(8), (Read full publication)

    Case Report

    1. Krishnamurthy J, Krishnamurty DM, Baker JJ, Zhen W, Lydiatt D, Ganti A (2013). Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature. Head & neck, 35(12), E372-5. (Read full publication)
    2. Kallam A, Krishnamurthy J, Kozel J, Shonka (2015). Undifferentiated Embryonal Sarcoma of Liver. Rare tumors, 7(4), 6009. (Read full publication)
    3. Kommalapati A, Kallam A, Krishnamurthy J, Tella SH, Koppala J, Tandra P (2018). Upper Limb Phlegmasia Cerulea Dolens Secondary to Heparin-induced Thrombocytopenia Leading to Gangrene. Cureus, 10(6), e2853. (Read full publication)
    4. Ghosh S, Bendi VS, Krishnamurthy J, Tandra P, Kommalapati (2018). Type 2M Von Willebrand Disease: A Case Report. Cureus, 10(8), e3112. (Read full publication)
    5. Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma C (2019). Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network, 17(2), 141-147. (Read full publication)

    Editorial

    1. Kesireddy M, Krishnamurthy (2024). Pregnancy-Associated Breast Cancer: Key Concepts for Optimizing Diagnosis and Treatment. JCO oncology practice, OP2400867. (Read full publication)
    2. Kesireddy M, Krishnamurthy (2025). T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective. Gland surgery, 14(4), 785-790. (Read full publication)

    Abstract

    1. Alves TF, Crosby K, Horner RD, Dai HD, Krishnamurthy J, Cozad MJ (2025). Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study. . 8;14(1):e66050,
    2. Louthan D, Sharifi MN, Danciu OC, Krishnamurthy J, Vasekar MK, Hoskins K, Lasarev M, Eikhoff J, O¿Regan RM, Wisinski KB, Truica CI (2025). Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409). . 31 (12_Supplement): P2¿09¿27,
    3. Krishnamurthy J, Elsayed L, Reed E, Modi S, Tandra P, Copur M, Samson K (2025). Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide with Trastuzumab in Stage I-III Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. 31 (12_Supplement): P4¿05¿05,